The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rising incidence of blood cancers, expansion of hospital diagnostic laboratories, increasing awareness of early cancer detection, growth in clinical research activities, availability of advanced testing reagents.
The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in genomic testing infrastructure, expansion of AI-driven diagnostic platforms, growing demand for companion diagnostics, continuous innovation in assay technologies. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, expansion of automated laboratory testing platforms, enhanced integration of data analytics in hemato-oncology.
The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, From 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.
Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.
In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.
Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health.
North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the hemato oncology testing market by increasing costs of imported reagents, sequencing instruments, laboratory automation systems, and analytical software components. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported high-end testing equipment, while Asia-Pacific faces cost pressures on reagent manufacturing and export. These tariffs are raising operational expenses and test pricing. However, they are also promoting domestic reagent production, regional equipment manufacturing, and localized development of diagnostic technologies.
The hemato oncology testing market research report is one of a series of new reports that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with a hemato oncology testing market share, detailed hemato oncology testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.
The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.
The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in genomic testing infrastructure, expansion of AI-driven diagnostic platforms, growing demand for companion diagnostics, continuous innovation in assay technologies. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, expansion of automated laboratory testing platforms, enhanced integration of data analytics in hemato-oncology.
The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, From 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.
Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.
In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.
Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health.
North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the hemato oncology testing market by increasing costs of imported reagents, sequencing instruments, laboratory automation systems, and analytical software components. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported high-end testing equipment, while Asia-Pacific faces cost pressures on reagent manufacturing and export. These tariffs are raising operational expenses and test pricing. However, they are also promoting domestic reagent production, regional equipment manufacturing, and localized development of diagnostic technologies.
The hemato oncology testing market research report is one of a series of new reports that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with a hemato oncology testing market share, detailed hemato oncology testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.
The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.
The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hemato Oncology Testing Market Characteristics
3. Hemato Oncology Testing Market Supply Chain Analysis
4. Global Hemato Oncology Testing Market Trends and Strategies
5. Hemato Oncology Testing Market Analysis of End Use Industries
7. Global Hemato Oncology Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hemato Oncology Testing Total Addressable Market (TAM) Analysis for the Market
9. Hemato Oncology Testing Market Segmentation
10. Hemato Oncology Testing Market Regional and Country Analysis
11. Asia-Pacific Hemato Oncology Testing Market
12. China Hemato Oncology Testing Market
13. India Hemato Oncology Testing Market
14. Japan Hemato Oncology Testing Market
15. Australia Hemato Oncology Testing Market
16. Indonesia Hemato Oncology Testing Market
17. South Korea Hemato Oncology Testing Market
18. Taiwan Hemato Oncology Testing Market
19. South East Asia Hemato Oncology Testing Market
20. Western Europe Hemato Oncology Testing Market
21. UK Hemato Oncology Testing Market
22. Germany Hemato Oncology Testing Market
23. France Hemato Oncology Testing Market
24. Italy Hemato Oncology Testing Market
25. Spain Hemato Oncology Testing Market
26. Eastern Europe Hemato Oncology Testing Market
27. Russia Hemato Oncology Testing Market
28. North America Hemato Oncology Testing Market
29. USA Hemato Oncology Testing Market
30. Canada Hemato Oncology Testing Market
31. South America Hemato Oncology Testing Market
32. Brazil Hemato Oncology Testing Market
33. Middle East Hemato Oncology Testing Market
34. Africa Hemato Oncology Testing Market
36. Hemato Oncology Testing Market Competitive Landscape and Company Profiles
37. Hemato Oncology Testing Market Other Major and Innovative Companies
40. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hemato Oncology Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hemato oncology testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemato oncology testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product And Services: Assay Kits And Reagents; Services2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma
3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS)
4) By End User: Hospitals; Academic And Research Institutes
Subsegments:
1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; Antibodies2) By Services: Testing Services; Data Analysis Services
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.; Qiagen N.V.; Bio-Rad Laboratories Inc.; Archerdx Inc.; ARUP Laboratories Inc.; Asuragen Inc.; Adaptive Biotechnologies Corp.; Cepheid Inc.; EntroGen Inc.; CORE Diagnostics Inc.; Genoptix Inc.; GenPath Diagnostics; NeoGenomics Laboratories Inc.; Siemens AG; Sysmex Corporation; Laboratory Corporation of America Holdings; Agilent Technologies; Danaher Corporation; Grifols SA; Diaorin SpA; HTG Molecular Diagnostics Inc.; Admera Health
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hemato Oncology Testing market report include:- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Invivoscribe Inc.
- Qiagen N.V.
- Bio-Rad Laboratories Inc.
- Archerdx Inc.
- ARUP Laboratories Inc.
- Asuragen Inc.
- Adaptive Biotechnologies Corp.
- Cepheid Inc.
- EntroGen Inc.
- CORE Diagnostics Inc.
- Genoptix Inc.
- GenPath Diagnostics
- NeoGenomics Laboratories Inc.
- Siemens AG
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Agilent Technologies
- Danaher Corporation
- Grifols SA
- Diaorin SpA
- HTG Molecular Diagnostics Inc.
- Admera Health
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.5 Billion |
| Forecasted Market Value ( USD | $ 7.76 Billion |
| Compound Annual Growth Rate | 14.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
